Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Contact lens legislation

This article was originally published in The Gray Sheet

Executive Summary

California Governor Gray Davis (D) signs bill Sept. 23 requiring ophthalmologists and optometrists to release contact lens prescriptions to patients. Sponsored by Lou Correa (D-Anaheim), AB 2020 is expected to help consumers buy their contacts through discount stores, mail order and online distributors. The bill also provides safeguards by requiring a valid prescription with an expiration date. On Sept. 4, lens maker J&J/Vistakon met with FDA, along with 1-800-Contacts and state attorneys general from Baltimore and New York, to discuss the firm's concerns about adequate eye care for lens wearers buying through alternative sources. The Federal Trade Commission will examine the issue during its Oct. 8-10 Internet anti-competition workshop in Washington, D.C. (1"The Gray Sheet" July 22, 2002, p. 11)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel